## **Core Concept**
Chronic gout management involves reducing serum urate levels to prevent gouty arthritis attacks and complications. In patients with renal impairment, the choice of urate-lowering therapy (ULT) is crucial as some drugs are contraindicated or require dose adjustment.

## **Why the Correct Answer is Right**
Febuxostat (**Option C**) is a xanthine oxidase inhibitor used in the treatment of gout. Unlike allopurinol, another xanthine oxidase inhibitor, febuxostat does not require dose adjustment in patients with mild to moderate renal impairment. It is specifically indicated for patients who are intolerant to allopurinol. Febuxostat effectively lowers serum uric acid levels and is well-tolerated in patients with renal impairment.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Allopurinol is a xanthine oxidase inhibitor but requires dose adjustment in renal impairment to avoid toxicity, making it less ideal for patients with renal issues.
- **Option B:** Probenecid increases uric acid excretion but is less effective in patients with renal impairment and is not typically used as a first-line agent in such cases.
- **Option D:** Sulfasalazine has mild urate-lowering effects but is not potent enough for the management of chronic gout and is not specifically indicated for patients with renal impairment.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that in patients with chronic gout and renal impairment, **febuxostat** is a preferred option due to its efficacy and safety profile. Always consider the patient's renal function when choosing a ULT.

## **Correct Answer:** C. Febuxostat.